Halozyme Therapeutics has been one of 2015’s hotter biotech stocks, but it’s not exactly because of developing a drug. Halozyme’s (HALO) one marketed product, Hylenex, aids in the delivery of injectable drugs. Halozyme has also licensed Enhanz for the same purpose to such drug companies as Pfizer (PFE), Roche (RHHBY), Johnson & Johnson ‘s (JNJ) Janssen division, AbbVie (ABBV) and Baxalta (BXLT) for the development of new injectable products. San
Biotech Halozyme Therapeutics (HALO) jumped as much as 18% Tuesday morning, nearly touching an all-time high, a day after the company beat Q2 estimates and provided an update on its pipeline. But shares reversed to close lower. Late Monday, Halozyme reported revenue of $43.4 million, up 136% from the year-earlier quarter and $18 million more than analysts expected. More than half the revenue came from a $23 million milestone payment from AbbVie
Biotech Halozyme Therapeutics (HALO) jumped 16% early Tuesday, nearly touching an all-time high, a day after the company beat Q2 estimates and provided an update on its pipeline. Late Monday, Halozyme reported revenue of $43.4 million, up 136% from the year-earlier quarter and $18 million more than analysts expected. More than half the revenue came from a $23 million milestone payment from AbbVie (ABBV) in June. A partnership between the two